Diese Seite wurde automatisch übersetzt und die Genauigkeit der Übersetzung wird nicht garantiert. Bitte wende dich an die englische Version für einen Quelltext.

PROTECT-HER KIT to Improve HPV Self-Sampling Uptake Among Women in Selangor (PROTECTHER KIT)

13. November 2026 aktualisiert von: Fairuz Alia Rafiai, Universiti Teknologi Mara

Development, Validation, and Evaluation of the Protection Motivation Theory-Based HPV Screening Education Kit (PROTECT-HER KIT) on HPV Self-Sampling Uptake Among the KOSPEN Community in Selangor: A Cluster Randomised Controlled Trial

This study aims to evaluate the effectiveness of the Protection Motivation Theory-Based HPV Screening Education Kit (PROTECT-HER KIT) in improving human papillomavirus (HPV) self-sampling uptake among eligible women in KOSPEN communities in Selangor, Malaysia. The study uses a two-arm, parallel cluster randomised controlled trial involving 106 women aged 30-65 years across eight KOSPEN localities. Localities will be randomly allocated to receive either the PROTECT-HER KIT educational intervention or standard Ministry of Health educational materials. The primary outcome is HPV self-sampling uptake assessed at one and two months following the intervention. Secondary outcomes include cervical cancer awareness and protection motivation measured at baseline, one month, and two months.

Studienübersicht

Detaillierte Beschreibung

The goal of this cluster randomised controlled trial is to evaluate the effectiveness of the Protection Motivation Theory-Based HPV Screening Education Kit (PROTECT-HER KIT) in improving human papillomavirus (HPV) self-sampling uptake, cervical cancer awareness, and protection motivation among eligible women in the Komuniti Sihat Pembina Negara (KOSPEN) communities in Selangor, Malaysia. The PROTECT-HER KIT is a newly developed health education package designed to improve women's knowledge, perceived risk, confidence, and motivation to undergo HPV self-sampling for cervical cancer screening.

The main questions this study aims to answer are:

Will the PROTECT-HER KIT increase HPV self-sampling uptake among eligible women in KOSPEN communities in Selangor?

Will the PROTECT-HER KIT improve cervical cancer awareness among participants?

Will the PROTECT-HER KIT improve protection motivation, including perceived severity, perceived vulnerability, response efficacy, self-efficacy, and perceived response costs related to HPV self-sampling?

To evaluate the effectiveness of the PROTECT-HER KIT, researchers will conduct a two-arm cluster randomised controlled trial involving eight KOSPEN localities in Selangor. The localities will be randomly assigned to either the intervention group or the control group. The intervention group will receive the PROTECT-HER KIT, comprising a structured face-to-face health education session using flipcharts, video demonstrations, facilitated discussions, and practical guidance on HPV self-sampling, followed by WhatsApp reinforcement messages and action-planning reminders. The control group will receive standard cervical cancer prevention educational materials from the Ministry of Health Malaysia.

Participants will:

Complete a baseline questionnaire (T0) assessing their sociodemographic characteristics, cervical cancer awareness, protection motivation, and previous cervical cancer screening history.

Receive either the PROTECT-HER KIT educational intervention or standard Ministry of Health educational materials, depending on the KOSPEN locality to which they belong.

Complete follow-up questionnaires at approximately one month (T1) and two months (T2) after the educational intervention to assess changes in cervical cancer awareness, protection motivation, and HPV self-sampling uptake.

Report whether they have undergone HPV self-sampling for cervical cancer screening during the follow-up period.

The findings will help determine whether a theory-based, community-delivered health education intervention can improve HPV self-sampling uptake and support cervical cancer prevention efforts in Malaysia.

Studientyp

Interventionell

Einschreibung (Geschätzt)

106

Phase

  • Unzutreffend

Kontakte und Standorte

Dieser Abschnitt enthält die Kontaktdaten derjenigen, die die Studie durchführen, und Informationen darüber, wo diese Studie durchgeführt wird.

Studienkontakt

Studienorte

    • Putrajaya
      • Petaling Jaya, Putrajaya, Malaysia, 40000
        • Pejabat Kesihatan Daerah Petaling
        • Kontakt:

Teilnahmekriterien

Forscher suchen nach Personen, die einer bestimmten Beschreibung entsprechen, die als Auswahlkriterien bezeichnet werden. Einige Beispiele für diese Kriterien sind der allgemeine Gesundheitszustand einer Person oder frühere Behandlungen.

Zulassungskriterien

Studienberechtigtes Alter

30 Jahre bis 65 Jahre (Erwachsene, Älterer Erwachsener)

Akzeptiert gesunde Freiwillige

Ja

Studienberechtigte Geschlechter

Weiblich

Beschreibung

Inclusion Criteria:

  1. Malaysian women aged 30-65 years.
  2. Residing in a participating KOSPEN locality in Selangor.
  3. Able to read and understand Malay.
  4. Never screened or overdue for cervical cancer screening according to current Malaysian guidelines.
  5. Own a smartphone with WhatsApp.

Exclusion Criteria:

  1. Physical or mental impairment preventing participation in study procedures.
  2. Declines to participate or provide informed consent.
  3. Diagnosed cervical cancer or precancerous cervical disease.

Studienplan

Dieser Abschnitt enthält Einzelheiten zum Studienplan, einschließlich des Studiendesigns und der Messung der Studieninhalte.

Wie ist die Studie aufgebaut?

Designdetails

  • Hauptzweck: Screening
  • Zuteilung: Zufällig
  • Interventionsmodell: Parallele Zuordnung
  • Maskierung: Single

Waffen und Interventionen

Teilnehmergruppe / Arm
Intervention / Behandlung
Experimental: PROTECT-HER KIT

Participants will receive a structured, approximately 90-minute face-to-face educational session incorporating four modules: cervical cancer and HPV risk education, HPV self-sampling procedures and skills, emotional and practical barriers, and action planning. Educational materials include flipcharts, video demonstrations, facilitated discussions and standardised WhatsApp reinforcement and reminders.

Participants allocated to the intervention group will receive the PROTECT-HER KIT, a structured educational intervention based on Protection Motivation Theory (PMT) to improve cervical cancer awareness, protection motivation, and HPV self-sampling uptake. The intervention consists of a single approximately 90-minute, face-to-face small-group educational session delivered by the principal researcher using flipcharts, a video demonstration, facilitated discussions, and practical guidance on HPV self-sampling. The educational content addresses perceived severity, perceived vulnerability, response efficacy, self-efficacy, and perceived response costs related to cervical cancer screening. Standardised WhatsApp reinforcement messages and action-planning reminders will be provided following the session to encourage HPV self-sampling uptake. The intervention will be delivered after completion of the baseline assessment (T0).

Aktiver Komparator: Standard Ministry of Health Education

Participants will receive a one-off distribution of existing Ministry of Health educational materials containing general information on women's health and cervical cancer prevention. Participants will continue to have access to routine cervical cancer screening services.

Participants allocated to the control group will receive a one-off distribution of standard health educational materials sourced from the Ministry of Health Malaysia. These materials provide general information on women's health, cervical cancer prevention, and cervical cancer screening. Unlike the intervention group, participants will not receive the structured PROTECT-HER KIT educational session or standardised WhatsApp reinforcement messages. The educational materials will be distributed once following completion of the baseline assessment (T0). Participants will continue to have access to routine cervical cancer screening services.

Was misst die Studie?

Primäre Ergebnismessungen

Ergebnis Maßnahme
Maßnahmenbeschreibung
Zeitfenster
Secondary: Cervical cancer awareness
Zeitfenster: Baseline, 1 and 2 months

Cervical Cancer Awareness Scale (Cx-CAS), 15 items

Baseline, 1 and 2 months

Sekundäre Ergebnismessungen

Ergebnis Maßnahme
Maßnahmenbeschreibung
Zeitfenster
Secondary: Cervical cancer awareness
Zeitfenster: Baseline, 1 and 2 months

Cervical Cancer Awareness Scale (Cx-CAS), 15 items

Baseline, 1 and 2 months
Secondary: Protection motivation
Zeitfenster: Baseline, 1 and 2 months

Adapted Malay PMT questionnaire, 24 items

Baseline, 1 and 2 months

Mitarbeiter und Ermittler

Hier finden Sie Personen und Organisationen, die an dieser Studie beteiligt sind.

Studienaufzeichnungsdaten

Diese Daten verfolgen den Fortschritt der Übermittlung von Studienaufzeichnungen und zusammenfassenden Ergebnissen an ClinicalTrials.gov. Studienaufzeichnungen und gemeldete Ergebnisse werden von der National Library of Medicine (NLM) überprüft, um sicherzustellen, dass sie bestimmten Qualitätskontrollstandards entsprechen, bevor sie auf der öffentlichen Website veröffentlicht werden.

Haupttermine studieren

Studienbeginn (Geschätzt)

1. März 2027

Primärer Abschluss (Geschätzt)

30. Juni 2027

Studienabschluss (Geschätzt)

30. Juni 2027

Studienanmeldedaten

Zuerst eingereicht

9. November 2026

Zuerst eingereicht, das die QC-Kriterien erfüllt hat

13. November 2026

Zuerst gepostet (Tatsächlich)

17. November 2026

Studienaufzeichnungsaktualisierungen

Letztes Update gepostet (Tatsächlich)

17. November 2026

Letztes eingereichtes Update, das die QC-Kriterien erfüllt

13. November 2026

Zuletzt verifiziert

1. November 2026

Mehr Informationen

Begriffe im Zusammenhang mit dieser Studie

Plan für individuelle Teilnehmerdaten (IPD)

Planen Sie, individuelle Teilnehmerdaten (IPD) zu teilen?

NEIN

Beschreibung des IPD-Plans

Individual participant data (IPD) will not be made publicly available due to the sensitive nature of the information collected, including cervical cancer screening history, HPV self-sampling uptake, and health-related perceptions. Data confidentiality and participant privacy will be maintained in accordance with the approved study protocol, institutional ethical requirements, and applicable data protection regulations. Study findings will be disseminated through scientific publications and presentations in aggregate form without identifying individual participants.

Arzneimittel- und Geräteinformationen, Studienunterlagen

Studiert ein von der US-amerikanischen FDA reguliertes Arzneimittelprodukt

Nein

Studiert ein von der US-amerikanischen FDA reguliertes Geräteprodukt

Nein

Diese Informationen wurden ohne Änderungen direkt von der Website clinicaltrials.gov abgerufen. Wenn Sie Ihre Studiendaten ändern, entfernen oder aktualisieren möchten, wenden Sie sich bitte an register@clinicaltrials.gov. Sobald eine Änderung auf clinicaltrials.gov implementiert wird, wird diese automatisch auch auf unserer Website aktualisiert .

Abonnieren